February 2015 | The Journal of Targeted Therapies in Cancer

Novel Targets in Relapsed and Relapsed/Refractory Multiple Myeloma

April 13, 2015

Article

Clinical Articles

Current approaches to the management of multiple myeloma (MM), in particular the introduction of proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs), have improved the survival of patients.

PARP-1 Inhibitors and Their Emerging Role in the Treatment of Lung Cancer

April 09, 2015

Article

Clinical Articles

Lung cancer is one of the leading causes of death worldwide. The standard of care for advanced small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) includes platinumbased chemotherapy.

The Potential of ADCs in the Treatment of Breast Cancer

April 06, 2015

Article

Clinical Articles

Targeted therapy through the use of antibody drug conjugates holds great promise for the treatment of many malignancies, in particular, breast cancer.

From the Editor: PARP Inhibitors, Biomarker Research, and Gene Editing

February 01, 2015

Article

Clinical Articles

Our physician editor-in-chief highlights the February 2015 issue of The Journal of Targeted Therapies in Cancer.